CoChat

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue

Dolled-Filhart, Marisa, Locke, Darren, Murphy, Tiffany, Lynch, Frank, Yearley, Jennifer H., Frisman, Dennis, Pierce, Robert, Weiner, Russell, Wu, Dianna, Emancipator, Kenneth · 2016 · Archives of Pathology & Laboratory Medicine
Cited by 92

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Context.—: With the abundance of therapeutics targeted against programmed death receptor-1 and its ligand (PD-L1) that are currently approved or in clinical development, there is interest in identifying those patients most likely to respond to these drugs. Expression of PD-L1 may be an indicator of an initial and robust inflammatory response to the presence of tumor cells. Therefore, tumors that express PD-L1 may be the most likely to respond to therapies that interrupt the negative feedback mechanism that leads to PD-L1 upregulation. Objective.—: To develop a prototype immunohistochemistry assay using the anti–PD-L1 antibody clone 22C3. Design.—: The assay was developed and optimized using commercially available reagents and archival tumor-bank tissue. Results.—: The optimized immunohistochemistry method had high precision and reproducibility. Using the prototype assay in 142 non–small cell lung cancer and 79 melanoma archival tumor-bank tissue samples, PD-L1 staining was observed at the plasma membrane of nucleated tumor and nontumor cells and, in some cases, as a distinct lichenoid pattern at the tumor-stroma border. Using a preliminary scoring method, 56% (80 of 142) of non–small cell lung cancer and 53% (42 of 79) of melanoma samples were defined as PD-L1+ based on a modified H-score of 1 or more or the presence of a distinctive staining pattern at the tumor-stroma interface. Conclusions.—: The immunohistochemistry assay using the anti–PD-L1 antibody 22C3 merits further investigation in clinical trials and prevalence assessments to further understand the prognostic and predictive value of PD-L1 expression in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5858/arpa.2015-0544-oa

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 92

Metadata

Authors
Dolled-Filhart, M., Locke, D., Murphy, T., Lynch, F., Yearley, J. H., Frisman, D., Pierce, R., Weiner, R., Wu, D., & Emancipator, K.
Venue
Archives of Pathology & Laboratory Medicine
Published
2016-11-01
Volume
140
Issue
11
Pages
1259-1266
ISSN
  • 0003-9985 (ISSN-L)
  • 1543-2165
OpenAlex
W2542773270
Cited by
92
References
3
FWCI
4.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. https://app.cochat.ai/papers/10.5858/arpa.2015-0544-oa
The paper
Dolled-Filhart, M., Locke, D., Murphy, T., Lynch, F., Yearley, J. H., Frisman, D., Pierce, R., Weiner, R., Wu, D., & Emancipator, K. (2016). Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2015-0544-oa

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.